Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno Sells 90,474 Shares

Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 90,474 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $15.00, for a total transaction of $1,357,110.00. Following the transaction, the chief executive officer now directly owns 268,585 shares in the company, valued at $4,028,775. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Paul Bolno also recently made the following trade(s):

• On Wednesday, August 21st, Paul Bolno sold 48,366 shares of Wave Life Sciences stock. The stock was sold at an average price of $5.78, for a total transaction of $279,555.48.

Wave Life Sciences Stock Up 4.8 %

NASDAQ WVE opened at $15.31 on Monday. The firm has a market cap of $1.88 billion, a P/E ratio of -29.44 and a beta of -1.10. The company’s 50 day moving average is $7.10 and its 200-day moving average is $6.22. Wave Life Sciences Ltd. has a 12-month low of $3.50 and a 12-month high of $15.92.

Wave Life Sciences (NASDAQ:WVE) last issued its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. The business had revenue of $19.69 million for the quarter, compared to the consensus estimate of $24.80 million. During the same period in the previous year, the firm earned ($0.20) EPS. Equities analysts expect that Wave Life Sciences Ltd. will post -1 EPS for the current year.

Institutional Trading of Wave Life Sciences

A number of institutional investors have recently added to or reduced their stakes in WVE. Mackenzie Financial Corp grew its holdings in Wave Life Sciences by 13.6% during the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after buying an additional 1,905 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Wave Life Sciences by 50.2% in the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock valued at $45,000 after acquiring an additional 2,451 shares during the period. Rhumbline Advisers boosted its position in shares of Wave Life Sciences by 3.4% in the second quarter. Rhumbline Advisers now owns 125,834 shares of the company’s stock valued at $628,000 after acquiring an additional 4,092 shares during the period. Swiss National Bank grew its stake in Wave Life Sciences by 2.7% during the first quarter. Swiss National Bank now owns 156,500 shares of the company’s stock valued at $966,000 after acquiring an additional 4,100 shares in the last quarter. Finally, Capstone Investment Advisors LLC increased its holdings in Wave Life Sciences by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 54,500 shares of the company’s stock worth $336,000 after acquiring an additional 4,500 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday. B. Riley lifted their target price on Wave Life Sciences from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Mizuho restated an “outperform” rating and set a $19.00 price target on shares of Wave Life Sciences in a research report on Tuesday, June 25th. Leerink Partners lifted their price objective on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $13.00 to $22.00 in a research report on Wednesday, October 16th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.56.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.